{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:14:18Z","timestamp":1792602858791,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>This manuscript summarizes novel clinical and interventional approaches in the management of chronic, nociceptive, and neuropathic pain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Pain can be defined as a feeling of physical or emotional distress caused by an external stimulus. Pain can be grouped into distinct types according to characteristics including neuropathic pain, which is a pain caused by disease or lesion in the sensory nervous system; nociceptive pain, which is pain that can be sharp, aching, or throbbing and is caused by injury to bodily tissues; and chronic pain, which is long lasting or persisting beyond 6\u00a0months. With improved understanding of different signaling systems for pain in recent years, there has been an upscale of methods of analgesia to counteract these pathological processes. Novel treatment methods such as use of cannabinoids, stem cells, gene therapy, nanoparticles, monoclonal antibodies, and platelet-rich plasma have played a significant role in improved strategies for therapeutic interventions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Although many management options appear to be promising, extensive additional clinical research is warranted to determine best practice strategies in the future for clinicians.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11916-024-01227-5","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T14:02:59Z","timestamp":1708610579000},"page":"321-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Recent Advances in Management of Neuropathic, Nociceptive, and Chronic Pain: A Narrative Review with Focus on Nanomedicine, Gene Therapy, Stem Cell Therapy, and Newer Therapeutic Options"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8104-3085","authenticated-orcid":false,"given":"Saurabh","family":"Kataria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0631-3570","authenticated-orcid":false,"given":"Utsav","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Yabut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3277-1471","authenticated-orcid":false,"given":"Jayshil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7529-3214","authenticated-orcid":false,"given":"Rajkumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8183-6480","authenticated-orcid":false,"given":"Savan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-2163","authenticated-orcid":false,"given":"Jeremiah Hilkiah","family":"Wijaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6762-5855","authenticated-orcid":false,"given":"Pankti","family":"Maniyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukti","family":"Karki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moinulhaq P.","family":"Makrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2464-0187","authenticated-orcid":false,"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"1227_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/j.pain.0000000000000454","volume":"157","author":"ASC Rice","year":"2016","unstructured":"\u2022\u2022 Rice ASC, Smith BH, Blyth FM. Pain and the global burden of disease. Pain. 2016;157:791\u2013796. This article provides a comprehensive and extensive summary of the Global Burden of Disease Study of 2013, published in Lancet, particularly pertaining to pain, and includes data from a 23-year period.","journal-title":"Pain"},{"key":"1227_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.15713\/ins.jcri.112","volume":"3","author":"K Kumar","year":"2016","unstructured":"Kumar K, Elavarasi P, David CM. Definition of pain and classification of pain disorders. J Adv Clin Res Insights. 2016;3:87\u201390.","journal-title":"J Adv Clin Res Insights"},{"key":"1227_CR3","unstructured":"Swieboda P, Filip R, Prystupa A, Drozd M. Assessment of pain: types, mechanism and treatment. Ann Agric Environ Med. 2013;Spec no. 1:2\u20137."},{"key":"1227_CR4","doi-asserted-by":"publisher","unstructured":"Boldt I, Eriks-Hoogland I, Brinkhof MW, de Bie R, Joggi D, von Elm E. Non-pharmacological interventions for chronic pain in people with spinal cord injury. Cochrane Database Syst Rev. 2014;(11):CD009177. Published 2014 Nov 28. https:\/\/doi.org\/10.1002\/14651858.CD009177.pub2.","DOI":"10.1002\/14651858.CD009177.pub2"},{"key":"1227_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h532","volume":"350","author":"MC Reid","year":"2015","unstructured":"Reid MC, Eccleston C, Pillemer K. Management of chronic pain in older adults. BMJ. 2015;350:h532.","journal-title":"BMJ"},{"key":"1227_CR6","doi-asserted-by":"publisher","first-page":"790747","DOI":"10.3389\/fendo.2021.790747","volume":"12","author":"R Bhandari","year":"2021","unstructured":"\u2022\u2022 Bhandari R, Sharma A, Kuhad A. Novel nanotechnological approaches for targeting dorsal root ganglion (DRG) in mitigating diabetic neuropathic pain (DNP). Front Endocrinol (Lausanne). 2021;12:790747. This article is an excellent review focusing on novel approaches such as the utilization of nanotechnological approaches such as nanoparticles, polymeric nanoparticles, inorganic nanoparticles, lipid nanoparticles, gene therapy (siRNA and miRNA), and extracellular vesicles and its targeted use in diabetic neuropathic pain.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1227_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.920824","volume":"13","author":"L Xiao","year":"2022","unstructured":"Xiao L, Cui J, Sun Z, et al. Therapeutic potential of nanotechnology-based approaches in osteoarthritis. Front Pharmacol. 2022;13: 920824.","journal-title":"Front Pharmacol"},{"key":"1227_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.760936","volume":"15","author":"C Hu","year":"2021","unstructured":"Hu C, He M, Xu Q, et al. Advances with non-coding RNAs in neuropathic pain. Front Neurosci. 2021;15: 760936.","journal-title":"Front Neurosci"},{"key":"1227_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.omtm.2020.06.018","volume":"18","author":"D Kim","year":"2020","unstructured":"Kim D, Kim KR, Kwon Y, et al. AAV-mediated combination gene therapy for neuropathic pain: GAD65, GDNF, and IL-10. Mol Ther Methods Clin Dev. 2020;18:473\u201383.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1227_CR10","doi-asserted-by":"publisher","first-page":"12267","DOI":"10.1002\/jcp.27972","volume":"234","author":"A Karimian","year":"2019","unstructured":"\u2022\u2022 Karimian A, Azizian K, Parsian H, et al. CRISPR\/Cas9 technology as a potent molecular tool for gene therapy. J Cell Physiol. 2019;234:12267\u201312277. Authors highlight the importance and clinical significance of CRISPR-Cas9 system which is used in genome editing and correction of casual mutations and provide details of how it can still be useful in cancer treatment which eventually cause cancer-related pain.","journal-title":"J Cell Physiol"},{"key":"1227_CR11","doi-asserted-by":"publisher","unstructured":"Joshi HP, Jo HJ, Kim YH, An SB, Park CK, Han I. Stem Cell Therapy for Modulating Neuroinflammation in Neuropathic Pain. Int J Mol Sci. 2021;22(9):4853. Published 2021 May 3. https:\/\/doi.org\/10.3390\/ijms22094853.","DOI":"10.3390\/ijms22094853"},{"key":"1227_CR12","volume":"13","author":"J Padda","year":"2021","unstructured":"Padda J, Khalid K, Zubair U, et al. Stem cell therapy and its significance in pain management. Cureus. 2021;13: e17258.","journal-title":"Cureus"},{"key":"1227_CR13","first-page":"479","volume":"6","author":"I Alkislar","year":"2021","unstructured":"Alkislar I, Miller AR, Hohmann AG, et al. Inhaled cannabis suppresses chemotherapy- induced neuropathic nociception by decoupling the raphe nucleus: a functional imaging study in rats. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6:479\u201389.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"1227_CR14","doi-asserted-by":"publisher","first-page":"108445","DOI":"10.1016\/j.neuropharm.2020.108445","volume":"185","author":"DV Atigari","year":"2021","unstructured":"\u2022\u2022 Atigari DV, Paton KF, Uprety R, et al. The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain. Neuropharmacology. 2021;185:108445. This article depicts the use of MP1104, an analogue of 3-iodobenzoyl naltrexamine, which is a mixed opioid receptor agonist which targets the kappa opioid receptor and delta opioid receptor (DOP), in a mouse model. It reveals important findings showing that MP1104 has antinociceptive effects and has less to no abuse potential.","journal-title":"Neuropharmacology"},{"key":"1227_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3389\/fbioe.2020.00682","volume":"8","author":"J Chen","year":"2020","unstructured":"Chen J, Jin T, Zhang H. Nanotechnology in chronic pain relief. Front Bioeng Biotechnol. 2020;8:682.","journal-title":"Front Bioeng Biotechnol"},{"key":"1227_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157341305774642939","volume":"1","author":"L Jia","year":"2005","unstructured":"Jia L. Nanoparticle formulation increases oral bioavailability of poorly soluble drugs: approaches experimental evidences and theory. Curr Nanosci. 2005;1:237\u201343.","journal-title":"Curr Nanosci"},{"key":"1227_CR17","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Bhansali D, Teng SL, Lee CS, Schmidt BL, Bunnett NW, Leong KW. Nanotechnology for Pain Management: Current and Future Therapeutic Interventions. Nano Today. 2021;39:101223. https:\/\/doi.org\/10.1016\/j.nantod.2021.101223. Excellent review on advances in nanoparticle-based drug delivery to reduce side effects, gene therapy to tackle the source of pain, and nanomaterial-based scavenging to proactively mediate pain signaling.","DOI":"10.1016\/j.nantod.2021.101223"},{"key":"1227_CR18","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1038\/s41467-019-10296-9","volume":"10","author":"C Zhao","year":"2019","unstructured":"Zhao C, Liu A, Santamaria CM, et al. Polymer-tetrodotoxin conjugates to induce prolonged duration local anesthesia with minimal toxicity. Nat Commun. 2019;10:2566.","journal-title":"Nat Commun"},{"key":"1227_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bja.2021.03.017","volume":"127","author":"K Meissner","year":"2021","unstructured":"Meissner K, Henthorn TK. How relevant is stereoselectivity to the side-effects of ketamine? Br J Anaesth. 2021;127:1\u20132.","journal-title":"Br J Anaesth"},{"key":"1227_CR20","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2147\/IJN.S400798","volume":"18","author":"H Zhang","year":"2023","unstructured":"Zhang H, Zhou P, Jiang Y, et al. Sustained-release esketamine based nanoparticle- hydrogel delivery system for neuropathic pain management. Int J Nanomedicine. 2023;18:1131\u201343.","journal-title":"Int J Nanomedicine"},{"key":"1227_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12951-022-01473-y","volume":"20","author":"S Babaie","year":"2022","unstructured":"Babaie S, Taghvimi A, Hong JH, et al. Recent advances in pain management based on nanoparticle technologies. J Nanobiotechnology. 2022;20:290.","journal-title":"J Nanobiotechnology"},{"key":"1227_CR22","first-page":"80","volume":"5","author":"M Kesmati","year":"2014","unstructured":"Kesmati M, Torabi M. Interaction between analgesic effect of nano and conventional size of zinc oxide and opioidergic system activity in animal model of acute pain. Basic Clin Neurosci. 2014;5:80\u20137.","journal-title":"Basic Clin Neurosci"},{"key":"1227_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/gt.2009.18","volume":"16","author":"JC Glorioso","year":"2009","unstructured":"\u2022\u2022 Glorioso JC, Fink DJ. Gene therapy for pain: introduction to the special issue. Gene Therapy. 2009;16:453\u2013454. This article highlights the significance of gene therapy as a potentially practical approach suitable for intervening in the treatment of chronic intractable pain.","journal-title":"Gene Therapy"},{"key":"1227_CR24","unstructured":"Moss JA. Gene therapy review. Radiol Technol. 2014;86(2):155\u2013184."},{"key":"1227_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/0971-6866.112870","volume":"19","author":"S Mali","year":"2013","unstructured":"\u2022\u2022 Mali S. Delivery systems for gene therapy. Indian J Hum Genet. 2013;19:3\u20138. Excellent review on the delivery routes and methods for gene transfer used in gene therapy, especially the DNA technology.","journal-title":"Indian J Hum Genet"},{"key":"1227_CR26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1097\/00000542-200106000-00029","volume":"94","author":"CL Wu","year":"2001","unstructured":"\u2022\u2022 Wu CL, Garry MG, Zollo RA, et al. Gene therapy for the management of pain: part I: methods and strategies. Anesthesiology. 2001;94:1119\u20131132. Forefront review by scholars explaining the concept and application of gene therapy for the management of pain and the basic technologies and methods available for gene transfer.","journal-title":"Anesthesiology"},{"key":"1227_CR27","first-page":"71","volume":"7","author":"JR Goss","year":"2014","unstructured":"Goss JR, Krisky D, Wechuck J, et al. Herpes simplex virus-based nerve targeting gene therapy in pain management. J Pain Res. 2014;7:71\u20139.","journal-title":"J Pain Res"},{"key":"1227_CR28","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1526-4637.2011.01120.x","volume":"12","author":"S Kumar","year":"2011","unstructured":"\u2022\u2022 Kumar S, Ruchi R, James SR, et al. Gene therapy for chronic neuropathic pain: how does it work and where do we stand today? Pain Med. 2011;12:808\u2013822. This article highlights the importance of gene therapy and talks about the studies that have shown benefits of gene therapy in animal models, and recently, phase 1 human trials using herpes simplex virus vector have been studied for intractable cancer pain.","journal-title":"Pain Med"},{"key":"1227_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/096368979900800102","volume":"8","author":"MJ Eaton","year":"1999","unstructured":"\u2022\u2022 Eaton MJ, Plunkett JA, Martinez MA, et al. Transplants of neuronal cells bioengineered to synthesize GABA alleviate chronic neuropathic pain. Cell Transplant. 1999;8:87\u2013101. This article showing the future path in late 1990s, which is the use of neural cell lines that are able to deliver inhibitory neurotransmitters, such as GABA, in a model of chronic pain offers a novel approach to pain management.","journal-title":"Cell Transplant"},{"key":"1227_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1006\/exnr.2000.7491","volume":"166","author":"K Ishii","year":"2000","unstructured":"Ishii K, Isono M, Inoue R, et al. Attempted gene therapy for intractable pain: dexamethasone-mediated exogenous control of beta-endorphin secretion in genetically modified cells and intrathecal transplantation. Exp Neurol. 2000;166:90\u20138.","journal-title":"Exp Neurol"},{"key":"1227_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2004.07.017","volume":"370","author":"H Duplan","year":"2004","unstructured":"Duplan H, Li RY, Vue C, et al. Grafts of immortalized chromaffin cells bio-engineered to improve met-enkephalin release also reduce formalin-evoked c-fos expression in rat spinal cord. Neurosci Lett. 2004;370:1\u20136.","journal-title":"Neurosci Lett"},{"key":"1227_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/71889","volume":"18","author":"D Luo","year":"2000","unstructured":"Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol. 2000;18:33\u20137.","journal-title":"Nat Biotechnol"},{"key":"1227_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0306-4522(02)00078-7","volume":"112","author":"MZ Yao","year":"2002","unstructured":"Yao MZ, Gu JF, Wang JH, et al. Interleukin-2 gene therapy of chronic neuropathic pain. Neuroscience. 2002;112:409\u201316.","journal-title":"Neuroscience"},{"key":"1227_CR34","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/sj.gt.3302244","volume":"11","author":"CM Wu","year":"2004","unstructured":"Wu CM, Lin MW, Cheng JT, et al. Regulated, electroporation-mediated delivery of pro- opiomelanocortin gene suppresses chronic constriction injury-induced neuropathic pain in rats. Gene Ther. 2004;11:933\u201340.","journal-title":"Gene Ther"},{"key":"1227_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrn1104","volume":"4","author":"BL Davidson","year":"2003","unstructured":"Davidson BL, Breakefield XO. Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci. 2003;4:353\u201364.","journal-title":"Nat Rev Neurosci"},{"key":"1227_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/83324","volume":"7","author":"MA Kay","year":"2001","unstructured":"Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7:33\u201340.","journal-title":"Nat Med"},{"key":"1227_CR37","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1073\/pnas.96.6.3211","volume":"96","author":"SP Wilson","year":"1999","unstructured":"Wilson SP, Yeomans DC, Bender MA, et al. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci USA. 1999;96:3211\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1227_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2003.10.008","volume":"9","author":"DC Yeomans","year":"2004","unstructured":"Yeomans DC, Jones T, Laurito CE, et al. Reversal of ongoing thermal hyperalgesia in mice by a recombinant herpesvirus that encodes human preproenkephalin. Mol Ther. 2004;9:24\u20139.","journal-title":"Mol Ther"},{"key":"1227_CR39","doi-asserted-by":"publisher","first-page":"7881","DOI":"10.1523\/JNEUROSCI.21-20-07881.2001","volume":"21","author":"J Braz","year":"2001","unstructured":"Braz J, Beaufour C, Coutaux A, et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci. 2001;21:7881\u20138.","journal-title":"J Neurosci"},{"key":"1227_CR40","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ymthe.2004.12.011","volume":"11","author":"A Meunier","year":"2005","unstructured":"Meunier A, Latremoliere A, Mauborgne A, et al. Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol Ther. 2005;11:608\u201316.","journal-title":"Mol Ther"},{"key":"1227_CR41","doi-asserted-by":"publisher","first-page":"6652","DOI":"10.1523\/JNEUROSCI.5530-07.2008","volume":"28","author":"M Chattopadhyay","year":"2008","unstructured":"\u2022\u2022 Chattopadhyay M, Mata M, Fink DJ. Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci. 2008;28:6652\u20138. This study provides in-depth review and analysis showing that a novel interaction exists between the \u03b4-opioid receptor and voltage-gated sodium channels and thus its utilization in chronic pain management.","journal-title":"J Neurosci"},{"key":"1227_CR42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0304-3959(02)00346-9","volume":"102","author":"S Hao","year":"2003","unstructured":"\u2022\u2022 Hao S, Mata M, Goins W, et al. Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain. 2003;102:135\u201342. It is the first study to demonstrate the effects of gene transfer to provide an analgesic effect in neuropathic pain via vectors.","journal-title":"Pain"},{"key":"1227_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1744-8069-4-8","volume":"4","author":"H Yang","year":"2008","unstructured":"Yang H, McNearney TA, Chu R, et al. Enkephalin-encoding herpes simplex virus-1 decreases inflammation and hotplate sensitivity in a chronic pancreatitis model. Mol Pain. 2008;4:8.","journal-title":"Mol Pain"},{"key":"1227_CR44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/hum.2008.094","volume":"20","author":"H Yokoyama","year":"2009","unstructured":"Yokoyama H, Sasaki K, Franks ME, et al. Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin. Hum Gene Ther. 2009;20:63\u201371.","journal-title":"Hum Gene Ther"},{"key":"1227_CR45","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/sj.mt.6300228","volume":"15","author":"Y Lu","year":"2007","unstructured":"Lu Y, McNearney TA, Lin W, et al. Treatment of inflamed pancreas with enkephalin encoding HSV-1 recombinant vector reduces inflammatory damage and behavioral sequelae. Mol Ther. 2007;15:1812\u20139.","journal-title":"Mol Ther"},{"key":"1227_CR46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ymthe.2005.08.023","volume":"13","author":"DC Yeomans","year":"2006","unstructured":"Yeomans DC, Lu Y, Laurito CE, et al. Recombinant herpes vector-mediated analgesia in a primate model of hyperalgesia. Mol Ther. 2006;13:589\u201397.","journal-title":"Mol Ther"},{"key":"1227_CR47","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1523\/JNEUROSCI.20-01-00427.2000","volume":"20","author":"DL Bennett","year":"2000","unstructured":"Bennett DL, Boucher TJ, Armanini MP, et al. The glial cell line-derived neurotrophic factor family receptor components are differentially regulated within sensory neurons after nerve injury. J Neurosci. 2000;20:427\u201337.","journal-title":"J Neurosci"},{"key":"1227_CR48","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1006\/exnr.1998.6797","volume":"151","author":"C Sommer","year":"1998","unstructured":"Sommer C, Schmidt C, George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol. 1998;151:138\u201342.","journal-title":"Exp Neurol"},{"key":"1227_CR49","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1523\/JNEUROSCI.23-07-02517.2003","volume":"23","author":"M Schafers","year":"2003","unstructured":"Schafers M, Svensson CI, Sommer C, et al. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci. 2003;23:2517\u201321.","journal-title":"J Neurosci"},{"key":"1227_CR50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.neulet.2004.12.064","volume":"379","author":"CI Svensson","year":"2005","unstructured":"Svensson CI, Schafers M, Jones TL, et al. Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci Lett. 2005;379:209\u201313.","journal-title":"Neurosci Lett"},{"key":"1227_CR51","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1111\/j.1460-9568.2005.04057.x","volume":"21","author":"ED Milligan","year":"2005","unstructured":"Milligan ED, Langer SJ, Sloane EM, et al. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci. 2005;21:2136\u201348.","journal-title":"Eur J Neurosci"},{"key":"1227_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1744-8069-1-9","volume":"1","author":"ED Milligan","year":"2005","unstructured":"Milligan ED, Sloane EM, Langer SJ, et al. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain. 2005;1:9.","journal-title":"Mol Pain"},{"key":"1227_CR53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pain.2005.02.009","volume":"115","author":"A Ledeboer","year":"2005","unstructured":"Ledeboer A, Sloane EM, Milligan ED, et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain. 2005;115:71\u201383.","journal-title":"Pain"},{"key":"1227_CR54","doi-asserted-by":"publisher","unstructured":"Biehl JK, Russell B. Introduction to stem cell therapy. J Cardiovasc Nurs. 2009;24(2):98\u2013105. https:\/\/doi.org\/10.1097\/JCN.0b013e318197a6a5.","DOI":"10.1097\/JCN.0b013e318197a6a5"},{"key":"1227_CR55","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.3171\/2013.6.FOCUS13235","volume":"35","author":"S Vadivelu","year":"2013","unstructured":"\u2022\u2022 Vadivelu S, Willsey M, Curry DJ, et al. Potential role of stem cells for neuropathic pain disorders. Neurosurg Focus. 2013;35:E11. Outstanding review by the authors on the current experimental therapies examining the use of stem cells for the treatment of neuropathic pain disorders.","journal-title":"Neurosurg Focus"},{"key":"1227_CR56","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3344\/kjp.2019.32.4.245","volume":"32","author":"YH Han","year":"2019","unstructured":"Han YH, Kim KH, Abdi S, et al. Stem cell therapy in pain medicine. Korean J Pain. 2019;32:245\u201355.","journal-title":"Korean J Pain"},{"key":"1227_CR57","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1097\/TP.0b013e3182298a15","volume":"92","author":"L Orozco","year":"2011","unstructured":"\u2022\u2022 Orozco L, Soler R, Morera C, et al. Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation. 2011;92:822\u20138. The authors carried out a pilot study with 10 patients and concluded that autologous bone marrow mesenchymal cells can be used as an alternative therapy for chronic back pain caused by degenerative disc disease.","journal-title":"Transplantation"},{"key":"1227_CR58","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s12015-010-9227-1","volume":"7","author":"M Dadon-Nachum","year":"2011","unstructured":"Dadon-Nachum M, Sadan O, Srugo I, et al. Differentiated mesenchymal stem cells for sciatic nerve injury. Stem Cell Rev Rep. 2011;7:664\u201371.","journal-title":"Stem Cell Rev Rep"},{"key":"1227_CR59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1749-8090-6-43","volume":"6","author":"GU Premaratne","year":"2011","unstructured":"Premaratne GU, Ma LP, Fujita M, et al. Stromal vascular fraction transplantation as an alternative therapy for ischemic heart failure: anti-inflammatory role. J Cardiothorac Surg. 2011;6:43.","journal-title":"J Cardiothorac Surg"},{"key":"1227_CR60","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/en.2003-1336","volume":"145","author":"JN Fain","year":"2004","unstructured":"Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273\u201382.","journal-title":"Endocrinology"},{"key":"1227_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027458","volume":"6","author":"K Naruse","year":"2011","unstructured":"Naruse K, Sato J, Funakubo M, et al. Transplantation of bone marrow-derived mononuclear cells improves mechanical hyperalgesia, cold allodynia and nerve function in diabetic neuropathy. PLoS ONE. 2011;6: e27458.","journal-title":"PLoS ONE"},{"key":"1227_CR62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fnint.2011.00079","volume":"5","author":"D Siniscalco","year":"2011","unstructured":"Siniscalco D, Giordano C, Galderisi U, et al. Long-lasting effects of human mesenchymal stem cell systemic administration on pain-like behaviors, cellular, and biomolecular modifications in neuropathic mice. Front Integr Neurosci. 2011;5:79.","journal-title":"Front Integr Neurosci"},{"key":"1227_CR63","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/stem.667","volume":"29","author":"W Guo","year":"2011","unstructured":"\u2022\u2022 Guo W, Wang H, Zou S, et al. Bone marrow stromal cells produce long-term pain relief in rat models of persistent pain. Stem Cells. 2011;29:1294\u2013303. These authors completed a study on rat models showing that bone marrow stromal cells have pain relieving effects and necessitate further clinical studies.","journal-title":"Stem Cells"},{"key":"1227_CR64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1755-7682-3-30","volume":"3","author":"TE Ichim","year":"2010","unstructured":"Ichim TE, Solano F, Lara F, et al. Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report. Int Arch Med. 2010;3:30.","journal-title":"Int Arch Med"},{"key":"1227_CR65","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2147\/JPR.S63361","volume":"7","author":"ER Vickers","year":"2014","unstructured":"Vickers ER, Karsten E, Flood J, et al. A preliminary report on stem cell therapy for neuropathic pain in humans. J Pain Res. 2014;7:255\u201363.","journal-title":"J Pain Res"},{"key":"1227_CR66","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1089\/ten.teb.2009.0825","volume":"16","author":"W Wagner","year":"2010","unstructured":"Wagner W, Ho AD, Zenke M. Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B Rev. 2010;16:445\u201353.","journal-title":"Tissue Eng Part B Rev"},{"key":"1227_CR67","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/jcp.20376","volume":"205","author":"V Vacanti","year":"2005","unstructured":"Vacanti V, Kong E, Suzuki G, et al. Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J Cell Physiol. 2005;205:194\u2013201.","journal-title":"J Cell Physiol"},{"key":"1227_CR68","doi-asserted-by":"publisher","first-page":"470983","DOI":"10.1155\/2014\/470983","volume":"2014","author":"S Franchi","year":"2014","unstructured":"\u2022\u2022 Franchi S, Castelli M, Amodeo G, et al. Adult stem cell as new advanced therapy for experimental neuropathic pain treatment. Biomed Res Int. 2014;2014:470983. These authors provide an in-depth review of usage of autologous stem cell transplant for alleviating neuropathic pain.","journal-title":"Biomed Res Int"},{"key":"1227_CR69","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.nurt.2009.07.007","volume":"6","author":"LS Sorkin","year":"2009","unstructured":"Sorkin LS, Yaksh TL. Behavioral models of pain states evoked by physical injury to the peripheral nerve. Neurotherapeutics. 2009;6:609\u201319.","journal-title":"Neurotherapeutics"},{"key":"1227_CR70","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/pme.12426","volume":"15","author":"A Leung","year":"2014","unstructured":"Leung A, Fallah A, Shukla S. Transcutaneous magnetic stimulation (TMS) in alleviating post-traumatic peripheral neuropathic pain States: a case series. Pain Med. 2014;15:1196\u20139.","journal-title":"Pain Med"},{"key":"1227_CR71","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S0140-6736(85)92413-4","volume":"1","author":"AT Barker","year":"1985","unstructured":"Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. Lancet. 1985;1:1106\u20137.","journal-title":"Lancet"},{"key":"1227_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-510X(00)00451-2","volume":"182","author":"S Pridmore","year":"2000","unstructured":"Pridmore S, Oberoi G. Transcranial magnetic stimulation applications and potential use in chronic pain: studies in waiting. J Neurol Sci. 2000;182:1\u20134.","journal-title":"J Neurol Sci"},{"key":"1227_CR73","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/j.1532-2149.2012.00150.x","volume":"16","author":"JP Lefaucheur","year":"2012","unstructured":"Lefaucheur JP, Ayache SS, Sorel M, et al. Analgesic effects of repetitive transcranial magnetic stimulation of the motor cortex in neuropathic pain: influence of theta burst stimulation priming. Eur J Pain. 2012;16:1403\u201313.","journal-title":"Eur J Pain"},{"key":"1227_CR74","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/j.neuroimage.2007.10.035","volume":"39","author":"WK Yoo","year":"2008","unstructured":"Yoo WK, You SH, Ko MH, et al. High frequency rTMS modulation of the sensorimotor networks: behavioral changes and fMRI correlates. Neuroimage. 2008;39:1886\u201395.","journal-title":"Neuroimage"},{"key":"1227_CR75","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1533-2500.2012.00562.x","volume":"13","author":"NM Marlow","year":"2013","unstructured":"Marlow NM, Bonilha HS, Short EB. Efficacy of transcranial direct current stimulation and repetitive transcranial magnetic stimulation for treating fibromyalgia syndrome: a systematic review. Pain Pract. 2013;13:131\u201345.","journal-title":"Pain Pract"},{"key":"1227_CR76","doi-asserted-by":"publisher","unstructured":"O'Connell NE, Marston L, Spencer S, DeSouza LH, Wand BM. Non-invasive brain stimulation techniques for chronic pain. Cochrane Database Syst Rev. 2018;3(3):CD008208. Published 2018 Mar 16. https:\/\/doi.org\/10.1002\/14651858.CD008208.pub4.","DOI":"10.1002\/14651858.CD008208.pub4"},{"key":"1227_CR77","first-page":"309","volume":"47","author":"NE O'Connell","year":"2011","unstructured":"O\u2019Connell NE, Wand BM, Marston L, et al. Non-invasive brain stimulation techniques for chronic pain. A report of a Cochrane systematic review and meta-analysis. Eur J Phys Rehabil Med. 2011;47:309\u201326.","journal-title":"Eur J Phys Rehabil Med"},{"key":"1227_CR78","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1177\/19322968211026943","volume":"15","author":"VP Rao","year":"2021","unstructured":"Rao VP, Satyarengga M, Lamos EM, et al. The use of transcutaneous magnetic stimulation to treat painful diabetic neuropathy. J Diabetes Sci Technol. 2021;15:1406\u20137.","journal-title":"J Diabetes Sci Technol"},{"key":"1227_CR79","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.nec.2014.07.007","volume":"25","author":"NA Young","year":"2014","unstructured":"Young NA, Sharma M, Deogaonkar M. Transcranial magnetic stimulation for chronic pain. Neurosurg Clin N Am. 2014;25:819\u201332.","journal-title":"Neurosurg Clin N Am"},{"key":"1227_CR80","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/sj.bjp.0707531","volume":"153","author":"J Guindon","year":"2008","unstructured":"Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008;153:319\u201334.","journal-title":"Br J Pharmacol"},{"key":"1227_CR81","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","volume":"232","author":"S Galiegue","year":"1995","unstructured":"Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54\u201361.","journal-title":"Eur J Biochem"},{"key":"1227_CR82","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bcp.2018.09.013","volume":"157","author":"J Manzanares","year":"2018","unstructured":"Manzanares J, Cabanero D, Puente N, et al. Role of the endocannabinoid system in drug addiction. Biochem Pharmacol. 2018;157:108\u201321.","journal-title":"Biochem Pharmacol"},{"key":"1227_CR83","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9- tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199\u2013215.","journal-title":"Br J Pharmacol"},{"key":"1227_CR84","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3389\/fimmu.2016.00222","volume":"7","author":"VL Wehbi","year":"2016","unstructured":"Wehbi VL, Tasken K. Molecular mechanisms for cAMP-mediated immunoregulation in T cells - role of anchored protein kinase A signaling units. Front Immunol. 2016;7:222.","journal-title":"Front Immunol"},{"key":"1227_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.101999","volume":"298","author":"K Ghosh","year":"2022","unstructured":"Ghosh K, Zhang GF, Chen H, et al. Cannabinoid CB2 receptors are upregulated via bivalent histone modifications and control primary afferent input to the spinal cord in neuropathic pain. J Biol Chem. 2022;298: 101999.","journal-title":"J Biol Chem"},{"key":"1227_CR86","doi-asserted-by":"publisher","first-page":"479","DOI":"10.17245\/jdapm.2021.21.6.479","volume":"21","author":"B Sainsbury","year":"2021","unstructured":"Sainsbury B, Bloxham J, Pour MH, et al. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta- analysis. J Dent Anesth Pain Med. 2021;21:479\u2013506.","journal-title":"J Dent Anesth Pain Med"},{"key":"1227_CR87","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/ejp.1605","volume":"24","author":"S Almog","year":"2020","unstructured":"\u2022\u2022 Almog S, Aharon-Peretz J, Vulfsons S, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: a randomized, double-blinded, placebo-controlled trial. Eur J Pain. 2020;24:1505\u20131516. Authors performed a feasibility trial which demonstrated that a metered-dose cannabis inhaler delivered precise and low THC doses, produced a dose-dependent and safe analgesic effect in patients with neuropathic pain\/complex-regional pain syndrome (CRPS).","journal-title":"Eur J Pain"},{"key":"1227_CR88","doi-asserted-by":"publisher","unstructured":"Brown JD. Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug-Drug Interactions. J Clin Med. 2020;9(4):919. Published 2020 Mar 27. https:\/\/doi.org\/10.3390\/jcm9040919.","DOI":"10.3390\/jcm9040919"},{"key":"1227_CR89","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","volume":"155","author":"O van Hecke","year":"2014","unstructured":"\u2022\u2022 van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155:654\u2013662. This is an extensive review on the epidemiological statistics of neuropathic pain.","journal-title":"Pain"},{"key":"1227_CR90","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40122-017-0091-4","volume":"6","author":"D Fornasari","year":"2017","unstructured":"Fornasari D. Pharmacotherapy for neuropathic pain: a review. Pain Ther. 2017;6:25\u201333.","journal-title":"Pain Ther"},{"key":"1227_CR91","doi-asserted-by":"publisher","unstructured":"Yu K, Niu X, He B. Neuromodulation Management of Chronic Neuropathic Pain in The Central Nervous system. Adv Funct Mater. 2020;30(37):1908999. https:\/\/doi.org\/10.1002\/adfm.201908999.","DOI":"10.1002\/adfm.201908999"},{"key":"1227_CR92","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/ner.13020","volume":"23","author":"M Hofmeister","year":"2020","unstructured":"\u2022\u2022 Hofmeister M, Memedovich A, Brown S, et al. Effectiveness of neurostimulation technologies for the management of chronic pain: a systematic review. Neuromodulation. 2020;23:150\u2013157. This article provides a comprehensive review on the state of the literature for clinical effectiveness of neurostimulation such as spinal cord and peripheral nerve stimulators, which are used for the management of chronic pain.","journal-title":"Neuromodulation"},{"key":"1227_CR93","doi-asserted-by":"publisher","first-page":"117","DOI":"10.31616\/asj.2019.0161","volume":"15","author":"MZ Baig","year":"2021","unstructured":"Baig MZ, Abdullah UEH, Muhammad A, et al. Use of platelet-rich plasma in treating low back pain: a review of the current literature. Asian Spine J. 2021;15:117\u201326.","journal-title":"Asian Spine J"},{"key":"1227_CR94","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13018-017-0521-3","volume":"12","author":"L Shen","year":"2017","unstructured":"Shen L, Yuan T, Chen S, et al. The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta- analysis of randomized controlled trials. J Orthop Surg Res. 2017;12:16.","journal-title":"J Orthop Surg Res"},{"key":"1227_CR95","doi-asserted-by":"publisher","unstructured":"Bhatia R, Chopra G. Efficacy of Platelet Rich Plasma via Lumbar Epidural Route in Chronic Prolapsed Intervertebral Disc Patients-A Pilot Study. J Clin Diagn Res. 2016;10(9):UC05-UC07. https:\/\/doi.org\/10.7860\/JCDR\/2016\/21863.8482.","DOI":"10.7860\/JCDR\/2016\/21863.8482"},{"key":"1227_CR96","doi-asserted-by":"publisher","first-page":"115","DOI":"10.21037\/jss.2018.03.04","volume":"4","author":"S Mohammed","year":"2018","unstructured":"\u2022\u2022 Mohammed S, Yu J. Platelet-rich plasma injections: an emerging therapy for chronic discogenic low back pain. J Spine Surg. 2018;4:115\u2013122. This is an evidence-based study providing a review the current literature on PRP therapy and its potential use in the treatment of chronic discogenic low back pain.","journal-title":"J Spine Surg"},{"key":"1227_CR97","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1051\/sicotj\/2016002","volume":"2","author":"M Hussein","year":"2016","unstructured":"Hussein M, Hussein T. Effect of autologous platelet leukocyte rich plasma injections on atrophied lumbar multifidus muscle in low back pain patients with monosegmental degenerative disc disease. Sicot j. 2016;2:12.","journal-title":"Sicot j"},{"key":"1227_CR98","doi-asserted-by":"publisher","first-page":"E345","DOI":"10.36076\/ppj.2017.E356","volume":"20","author":"A Navani","year":"2017","unstructured":"Navani A, Li G, Chrystal J. Platelet rich plasma in musculoskeletal pathology: a necessary rescue or a lost cause? Pain Physician. 2017;20:E345-e356.","journal-title":"Pain Physician"},{"key":"1227_CR99","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00264-017-3422-5","volume":"41","author":"M Krsticevic","year":"2017","unstructured":"Krsticevic M, Jeric M, Dosenovic S, et al. Proliferative injection therapy for osteoarthritis: a systematic review. Int Orthop. 2017;41:671\u20139.","journal-title":"Int Orthop"},{"key":"1227_CR100","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/CIA.S147757","volume":"13","author":"P Rahimzadeh","year":"2018","unstructured":"Rahimzadeh P, Imani F, Faiz SHR, et al. The effects of injecting intra-articular platelet-rich plasma or prolotherapy on pain score and function in knee osteoarthritis. Clin Interv Aging. 2018;13:73\u20139.","journal-title":"Clin Interv Aging"},{"key":"1227_CR101","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.pmr.2016.06.001","volume":"27","author":"KD Reeves","year":"2016","unstructured":"Reeves KD, Sit RW, Rabago DP. Dextrose prolotherapy: a narrative review of basic science, clinical research, and best treatment recommendations. Phys Med Rehabil Clin N Am. 2016;27:783\u2013823.","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"1227_CR102","doi-asserted-by":"publisher","unstructured":"S\u00e1nchez-Robles EM, Gir\u00f3n R, Paniagua N, Rodr\u00edguez-Rivera C, Pascual D, Goicoechea C. Monoclonal Antibodies for Chronic Pain Treatment: Present and Future. Int J Mol Sci. 2021;22(19):10325. Published 2021 Sep 25. https:\/\/doi.org\/10.3390\/ijms221910325.","DOI":"10.3390\/ijms221910325"},{"key":"1227_CR103","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/jnc.13434","volume":"136","author":"FF Zhang","year":"2016","unstructured":"Zhang FF, Morioka N, Harano S, et al. Perineural expression of high-mobility group box-1 contributes to long-lasting mechanical hypersensitivity via matrix metalloprotease-9 up- regulation in mice with painful peripheral neuropathy. J Neurochem. 2016;136:837\u201350.","journal-title":"J Neurochem"},{"key":"1227_CR104","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1110\/ps.035402.108","volume":"17","author":"YN Abdiche","year":"2008","unstructured":"Abdiche YN, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci. 2008;17:1326\u201335.","journal-title":"Protein Sci"},{"key":"1227_CR105","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s40265-014-0208-6","volume":"74","author":"B Bannwarth","year":"2014","unstructured":"\u2022\u2022 Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs. 2014;74:619\u201326. An excellent review on effects of nerve growth factors on pain management.","journal-title":"Drugs"},{"key":"1227_CR106","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/0063030-200822060-00002","volume":"22","author":"JJ Watson","year":"2008","unstructured":"Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs. 2008;22:349\u201359.","journal-title":"BioDrugs"},{"key":"1227_CR107","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.neuron.2006.09.021","volume":"52","author":"JN Campbell","year":"2006","unstructured":"Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52:77\u201392.","journal-title":"Neuron"},{"key":"1227_CR108","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1742-2094-7-27","volume":"7","author":"L Leung","year":"2010","unstructured":"Leung L, Cahill CM. TNF-alpha and neuropathic pain\u2013a review. J Neuroinflammation. 2010;7:27.","journal-title":"J Neuroinflammation"},{"key":"1227_CR109","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1073\/pnas.1011774108","volume":"108","author":"A Hess","year":"2011","unstructured":"Hess A, Axmann R, Rech J, et al. Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci USA. 2011;108:3731\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1227_CR110","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low- dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552\u201363.","journal-title":"Arthritis Rheum"},{"key":"1227_CR111","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/papr.12078","volume":"13","author":"M Dirckx","year":"2013","unstructured":"Dirckx M, Groeneweg G, Wesseldijk F, et al. Report of a preliminary discontinued double- blind, randomized, placebo-controlled trial of the anti-TNF-alpha chimeric monoclonal antibody infliximab in complex regional pain syndrome. Pain Pract. 2013;13:633\u201340.","journal-title":"Pain Pract"},{"key":"1227_CR112","doi-asserted-by":"publisher","first-page":"174480691774023","DOI":"10.1177\/1744806917740233","volume":"13","author":"JF Yeh","year":"2017","unstructured":"\u2022\u2022 Yeh JF, Akinci A, Al Shaker M, et al. Monoclonal antibodies for chronic pain: a practical review of mechanisms and clinical applications. Mol Pain. 2017;13:1744806917740233. This article comprises of an in-depth comprehensive review on practical usage of monoclonal antibodies in clinical development for use in chronic pain conditions.","journal-title":"Mol Pain"},{"key":"1227_CR113","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/cpt.20","volume":"97","author":"B Bannwarth","year":"2015","unstructured":"Bannwarth B, Kostine M. Biologics in the treatment of chronic pain: a new era of therapy? Clin Pharmacol Ther. 2015;97:122\u20134.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-024-01227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-024-01227-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-024-01227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T18:28:49Z","timestamp":1716575329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-024-01227-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":113,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1007\/s11916-024-01227-5","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"4 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}